

Infliximab Injection Request

Please Fax Response to: 1-866-668-1214

Please Print. Please provide the information below. PRINT your answers, **attach supporting documentation**, sign, date, and return to our office as soon as possible to expedite this request.

Without this information, the request may be denied in 30 days.

Date of request	Client name	ProviderOne client ID																		
Prescriber's name		Billing provider NPI number																		
Telephone number	FAX number	Drug/strength/dose (Procedure/HCPC Code: J1745)																		
Request for: <input type="checkbox"/> Remicade <input type="checkbox"/> Inflectra Other: _____																				
Indicate patient's diagnosis For the following diagnoses patient must have tried and failed Humira : <input type="checkbox"/> Crohn's disease <input type="checkbox"/> Ulcerative colitis For the following diagnoses patient must have tried and failed Humira and Enbrel : <input type="checkbox"/> Rheumatoid arthritis (RA) <input type="checkbox"/> Ankylosing spondylitis <input type="checkbox"/> Psoriatic arthritis <input type="checkbox"/> Plaque psoriasis <input type="checkbox"/> Other: _____ Must provide justification for off-label use.																				
Please indicate what your patient has tried and failed (check all that apply): <table style="width: 100%; border: none;"> <tr> <td><input type="checkbox"/> Actemra (tocilizumab)</td> <td><input type="checkbox"/> Cimzia (certolizumab pegol)</td> <td><input type="checkbox"/> Cosentyx (secukinumab)</td> </tr> <tr> <td><input type="checkbox"/> Enbrel/Sureclick (etanercept)</td> <td><input type="checkbox"/> Entyvio (vedolizumab)</td> <td><input type="checkbox"/> Humira/Pen (adalimumab)</td> </tr> <tr> <td><input type="checkbox"/> Ilaris (canakinumab)</td> <td><input type="checkbox"/> Inflectra (infliximab-dyyb)</td> <td><input type="checkbox"/> Kineret (anakinra)</td> </tr> <tr> <td><input type="checkbox"/> Orencia/Clickjet (abatacept)</td> <td><input type="checkbox"/> Otezla (apremilast)</td> <td><input type="checkbox"/> Remicade (infliximab)</td> </tr> <tr> <td><input type="checkbox"/> Rituxan (rituximab)</td> <td><input type="checkbox"/> Simponi (golimumab)</td> <td><input type="checkbox"/> Stelara/IV (ustekinumab)</td> </tr> <tr> <td><input type="checkbox"/> Taltz (ixekizumab)</td> <td><input type="checkbox"/> Xeljanz/XR (tofacitinib citrate)</td> <td><input type="checkbox"/> Other: _____</td> </tr> </table>			<input type="checkbox"/> Actemra (tocilizumab)	<input type="checkbox"/> Cimzia (certolizumab pegol)	<input type="checkbox"/> Cosentyx (secukinumab)	<input type="checkbox"/> Enbrel/Sureclick (etanercept)	<input type="checkbox"/> Entyvio (vedolizumab)	<input type="checkbox"/> Humira/Pen (adalimumab)	<input type="checkbox"/> Ilaris (canakinumab)	<input type="checkbox"/> Inflectra (infliximab-dyyb)	<input type="checkbox"/> Kineret (anakinra)	<input type="checkbox"/> Orencia/Clickjet (abatacept)	<input type="checkbox"/> Otezla (apremilast)	<input type="checkbox"/> Remicade (infliximab)	<input type="checkbox"/> Rituxan (rituximab)	<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> Stelara/IV (ustekinumab)	<input type="checkbox"/> Taltz (ixekizumab)	<input type="checkbox"/> Xeljanz/XR (tofacitinib citrate)	<input type="checkbox"/> Other: _____
<input type="checkbox"/> Actemra (tocilizumab)	<input type="checkbox"/> Cimzia (certolizumab pegol)	<input type="checkbox"/> Cosentyx (secukinumab)																		
<input type="checkbox"/> Enbrel/Sureclick (etanercept)	<input type="checkbox"/> Entyvio (vedolizumab)	<input type="checkbox"/> Humira/Pen (adalimumab)																		
<input type="checkbox"/> Ilaris (canakinumab)	<input type="checkbox"/> Inflectra (infliximab-dyyb)	<input type="checkbox"/> Kineret (anakinra)																		
<input type="checkbox"/> Orencia/Clickjet (abatacept)	<input type="checkbox"/> Otezla (apremilast)	<input type="checkbox"/> Remicade (infliximab)																		
<input type="checkbox"/> Rituxan (rituximab)	<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> Stelara/IV (ustekinumab)																		
<input type="checkbox"/> Taltz (ixekizumab)	<input type="checkbox"/> Xeljanz/XR (tofacitinib citrate)	<input type="checkbox"/> Other: _____																		
What were the results of the trial(s)? If patient has not tried and failed per the requirements above based on diagnosis, please explain why not:																				
Patient's weight in kilograms (kg):	Pounds (lb):	Date weight was taken:																		
Results of the most recent annual TB test:		Date taken:																		

FDA approved dosing:

- Crohn's disease:
 - Maximum dose of 10mg/kg given every 8 weeks.
- Ulcerative colitis:
 - Maximum dose of 5mg/kg given at weeks 2 and weeks 6 of therapy and 5mg/kg given every 8 weeks after the induction regimen.
- Rheumatoid arthritis (RA):
 - Maximum dose of 10mg/kg given every 4 weeks.
- Ankylosing spondylitis:
 - Maximum dose of 5mg/kg given at week 2 and week 6 of therapy and 5mg/kg given every 8 weeks after the induction regimen.
- Psoriatic arthritis and Plaque psoriasis:
 - Maximum dose of 5mg/kg given at weeks 2 and weeks 6 of therapy and 5mg/kg given every 8 weeks after the induction regimen.

Is patient within the FDA approved dosing as per above? Yes No

Please provide dosing schedule:

New start: Dose: Frequency:

Continuation: Dose: Frequency: Date of last dose:

If over maximum dosing, must provide justification and documentation for off-label dosing.

Prescriber signature

Prescriber specialty

Date

A typed and completed *General Authorization for Information* form (13-835) must be attached to your request.

Fax to: 1-866-668-1214